Cancer Medicine · uk
When Should Abdominal Pain and Bloating Prompt Referral? UK Launches Multi-Cancer Blood Test Trial Involving More Than 20,000 People
STRIDE-RCT will bring new blood tests into GP practices to assess whether they can identify patients who need cancer investigations earlier. Participants already have abdominal symptoms, and whether testing can improve referral and diagnosis remains to be clinically validated.
Persistent bloating or abdominal pain may stem from common conditions, but they can also be vague signs of cancer. For GPs, the challenge is identifying people who need further investigation in a timely manner. On November 4, the UK’s National Health Service (NHS) announced the launch of STRIDE-RCT, which will assess whether multi-cancer blood tests can provide a more reliable basis for these decisions in routine consultations.
Led by the University of Birmingham, the trial plans to recruit more than 20,000 patients aged over 45 who seek care for abdominal symptoms through at least 200 GP practices in England. The study covers multiple cancers, including ovarian, bowel, pancreatic, stomach and liver cancers. Its focus is on helping people who already have symptoms receive appropriate investigations, rather than population-wide screening of people without symptoms.
Most of the tests being evaluated require only one or two additional tubes of blood during a routine blood draw. They look for signals of multiple cancers in the same sample and attempt to indicate the likely site of origin. Technologies described by officials and the university include measuring proteins in the blood and using artificial intelligence for analysis. However, the announcements have not yet provided accuracy data for individual tests, AI training data or external validation results, so it is currently impossible to determine which approach can best improve decisions in GP consultations.
The central question is whether test results, considered alongside existing investigations and doctors’ clinical judgment, can more clearly distinguish who needs an urgent referral. Co-lead Aneel Bhangu, a professor at the University of Birmingham, noted that some cancer patients experience months of symptoms that are difficult to explain before receiving a diagnosis, while many people referred urgently ultimately do not have cancer. Whether blood tests can narrow this gap in decision-making is precisely what the trial seeks to answer.
The ovarian cancer advocacy organisation Ovarian Cancer Action specifically cautions that a positive result does not mean a confirmed cancer diagnosis, and a negative result cannot guarantee the absence of cancer. Testing provides supporting information for referral decisions, rather than a definitive diagnosis. This also means that assessing its value requires considering not only how many cancers it can detect, but also the possibility of missed cases and additional investigations.
STRIDE-RCT uses a cluster platform trial design. According to the University of Birmingham’s research record, the project runs from November 1, 2026, to October 31, 2031. The UK’s Office for Life Sciences is providing up to £8.49 million in funding through the National Institute for Health and Care Research (NIHR). Participating practices will cover city centres, rural and coastal areas, and communities with fewer resources, allowing the study to better reflect differences across the population served by the NHS.
This announcement marks the launch of the trial. There is no evidence yet that this approach has shortened the time to diagnosis, reduced the proportion of late-stage cancers or improved survival. The findings will inform the NHS’s assessment of whether to expand its use. The real test is whether clues from a tube of blood can translate into more timely and appropriate follow-up investigations in busy GP practices.